Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
Sponsor: SIGA Technologies
Summary
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
Official title: Double-blind, Randomized, Placebo-controlled, Escalating, Multiple-dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetics of ST-246 Administered as a Single Daily Dose for 21 Days in Healthy, Non-fasted Volunteers
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2007-02
Completion Date
2008-02
Last Updated
2026-10-01
Healthy Volunteers
Yes
Conditions
Interventions
ST-246
250 mg, 400 mg or 800 mg capsules given once daily for 21 days
Placebo
Capsules to match experimental drug
Locations (1)
Orlando Clinical Research
Orlando, Florida, United States